蒽环类药物所致心脏毒性的研究进展  

Research progress on cardiotoxicity caused by anthracycline

作　　者：彭韵朴(综述) 周珏珉(审校) PENG Yun-pu;ZHOU Jue-min(Department of Cardiology,Suining Central Hospital,Suining 629000,Sichuan,CHINA)

机构地区：[1]遂宁市中心医院心内科,四川遂宁629000

出　　处：《海南医学》2021年第19期2550-2554,共5页Hainan Medical Journal

摘　　要：蒽环类药物是治疗恶性肿瘤最有效的化疗药物之一。而心脏毒性是蒽环类药物潜在的严重不良反应,无论预后如何,都会影响癌症患者的生活质量和生存率,从而限制蒽环类药物的临床应用。蒽环类药物所致心脏毒性可能是一种持续的现象,先从心肌细胞损伤开始,然后是左心室射血分数(LVEF)下降,不及早诊断和治疗,会逐渐发展为症状性心力衰竭。本文从作用机制、分类、危险因素、诊断标准、治疗和有效的预防措施等方面对蒽环类药物引起的心脏毒性进行综述。此外,还讨论了现行分类方法的局限性,新分类方法的必要性,以及早期心脏毒性检测和治疗的方法。Anthracycline is one of the most effective chemotherapeutic drugs in the treatment of malignant tumors.Cardiotoxicity is a potentially serious adverse reaction of anthracyclines.Regardless of the oncological prognosis,it will affect the quality of life and survival rate of cancer patients,thus limiting the clinical application of anthracyclines.Anthracycline-induced cardiotoxicity may be a continuous phenomenon.It starts with myocardial cell injury and then decreases in left ventricular ejection fraction(LVEF).Without early diagnosis and treatment,it will gradually develop into symptomatic heart failure.The article reviews the anthracycline-induced cardiotoxicity from the aspects of mechanism of action,classification,risk factors,diagnostic criteria,treatment and effective preventive strategies.In addition,the limitations of current classification methods,the necessity of new classification,and the methods of early cardiotoxicity detection and treatment are also discussed.

关 键 词：心脏毒性 蒽环类药物 早期检测 肌钙蛋白 左心室射血分数 

分 类 号：R979.1[医药卫生—药品]